Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211622 | 1.00 | KDM4E (0.44) | KDM4EATMGAAL3MBTL1ALDH1A1 | |
| SCHEMBL11461186 | 1.00 | KDM4E (0.44) | KDM4EATMGAAL3MBTL1ALDH1A1 | |
| SCHEMBL11457855 | 1.00 | KDM4E (0.44) | KDM4EATMGAAL3MBTL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11271861 | 0.97 | KDM4E (0.43) | KDM4EATMGAAL3MBTL1ALDH1A1 | |
| SCHEMBL5226180 | 0.97 | — | — | |
| SCHEMBL6026665 | 0.92 | — | — | |
| SCHEMBL6026521 | 0.86 | — | — | |
| SCHEMBL22901392 | 0.85 | KDM4E (0.35) | KDM4EATMGAAL3MBTL1ALDH1A1 | |
| Bromide SCHEMBL2833944 | 0.83 | — | — | |
| SCHEMBL18732943 | 0.81 | KDM4E (0.39) | KDM4EATMGAAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167489-B1 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-1957442-B1 | PROCESS FOR PREPARING SULFURIC MONOESTERS FROM AMINO ALKANOLS | BASF SE (DE) | 2015-11-11 | — | — | EP | disclosed |
| US-7888524-B2 | Process for preparing sulfuric monoesters from amino alkanols | BASF AKTIENGESELLSCHAFT (DE) | 2011-02-15 | — | — | US | disclosed |
| US-20080319215-A1 | Process For Preparing Sulfuric Monoesters From Amino Alkanols | BASF SE (DE) | 2008-12-25 | — | — | US | disclosed |
| EP-1957442-A1 | PROCESS FOR PREPARING SULFURIC MONOESTERS FROM AMINO ALKANOLS | BASF SE (DE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007063032-A1 | PROCESS FOR PREPARING SULFURIC MONOESTERS FROM AMINO ALKANOLS | BASF SE (DE) | 2007-06-07 | — | — | WO | disclosed |
| US-4330480-A | Preparation of aminoalkyl half-esters of sulfuric acid | BASF AKTIENGESELLSCHAFT (DE) | 1982-05-18 | — | — | US | disclosed |
| US-4223138-A | VAPORIZATION, CONDENSATION, RETARDING FLOW TO REACTION ZONE | BAYER AKTIENGESELLSCHAFT (DE) | 1980-09-16 | — | — | US | disclosed |
| US-3977994-A | Rust inhibiting composition | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319215-A1 | Process For Preparing Sulfuric Monoesters From Amino Alkanols | AASDHPPT, ALAD, ALDH7A1 | KDM4E 3584/4885ATM 420/4885GAA 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.